$dcth
Delcath Systems sees a massive 622% surge in engagements driven by X posts detailing procedure numbers and expanding center openings. However, recent portfolio updates show DCTH experiencing a -5.5% decline.
About $dcth
Delcath Systems is a medical technology company specializing in cancer treatments, particularly for liver cancers.
Insights
- $dcth engagements is up 622.12% from the previous week.
Engagements: [-----] (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [------]
[--] Week: [---] +622%
[--] Month: [------] -70%
[--] Months: [---------] -33%
[--] Year: [---------] +61%
1-Year High: [-------] on 2025-03-05
1-Year Low: [---] on 2025-04-22
Engagements by network (24h): YouTube: [--] Reddit: [--] X: [-----]
Mentions: [--] (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: [--]
Daily Average: [--]
1-Year High: [---] on 2025-11-22
1-Year Low: [--] on 2025-09-14
Mentions by network (24h): YouTube: [--] Reddit: [--] X: [--]
Creators: [--] (24h)
Creators 24-Hour Time-Series Raw Data
[--] unique social accounts have posts mentioning $dcth in the last [--] hours which is up 3.20% from [--] in the previous [--] hours
Daily Average: [--]
1-Year High: [---] on 2025-06-29
1-Year Low: [--] on 2025-04-12
The most influential creators that mention $dcth in the last [--] hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @Fund_Stocks | [--] | [--] | [--] | [---] |
| @NightOwlBiotech | [--] | [-----] | [--] | [---] |
| @ryshab | [--] | [-----] | [--] | [--] |
| @Yam_Trades | [--] | [-----] | [--] | [--] |
| @Rakufl47519 | [--] | [--] | [--] | [--] |
| @seedy19tron | [--] | [------] | [--] | [--] |
| @grok | [--] | [---------] | [--] | [--] |
| @BiopharmIQ | [--] | [------] | [--] | [--] |
Sentiment: 60%
Sentiment 24-Hour Time-Series Raw Data
Current Value: 60%
Daily Average: 84%
[--] Week: 50% -50%
[--] Month: 60% +17%
[--] Months: 60% -40%
[--] Year: 60% -40%
1-Year High: 100% on 2025-02-16
1-Year Low: 9% on 2025-12-18
Most Supportive Themes:
- FDA-Approved Product and Revenue Story: (25%) Delcath has an FDA-approved product, HEPZATO KIT, for liver-dominant uveal melanoma, positioning it as a revenue-generating company rather than a preclinical one.
- Expansion into New Indications: (20%) Management is targeting additional indications for their platform, such as colorectal liver metastases, which could lead to a high-margin franchise.
- Undervalued with Upcoming Catalysts: (20%) The company is considered undervalued with anticipated catalysts, attracting investors looking for potential growth opportunities.
- Long-term Hold Potential: (15%) The stock is viewed as a long-term hold due to its unique position in the MedTech space, offering a contrast to the higher risks associated with biotech.
- Informative Podcast Discussion: (10%) A podcast discussed the Chopin trial, providing informative insights into the company's developments.
Most Critical Themes:
- MedTech Risks: (50%) While distinct from biotech risks, the company operates within the MedTech sector, which inherently carries its own set of risks.
- Management Blackout Period: (50%) Potential weakness in the stock may be linked to management entering a blackout period, which could pause buyback activities.
Top $dcth Social Posts
Top posts by engagements in the last [--] hours
Showing a maximum of [--] top social posts without a LunarCrush subscription.
"$Dcth presentation today didnt see the whole presentation things I heard 4-6 procedures per month for Dr padia [--] procedures so far in about 28-29 patients. First procedure he did was April [--] [--]. Says he is booked for February and March his backlog isnt insane anymore due to more and more centers opening on the West Coast. Seemed to imply they definitely could do more than 4-6 per month but at the end of the day they need room time and that is about what works best for the center right now. Sites are openly rapidly quote https://twitter.com/i/web/status/2022730174039839091"
X Link @mike98572986 2026-02-14T17:50Z [----] followers, [----] engagements
"Weekly Portfolio Performance: $HROW: +15.6% $PSIX: +13% $SEZL: +7.1% $QXO: +3.7% $CRMD: -0.9% $DCTH: -5.5% $VIST: -7.5% $MSTR: -9.9% $IREN: -22.2% Im actually more bullish about $IREN after the report only logical from long term perspective. NFA. DYOR. Weekly Portfolio Performance: $VIST: +14.3% $CRMD: +6.7% $IREN: -5.2% $DCTH: [----] $SEZL: -6.5% $PSIX: -7.3% $QXO: -7.3% $HROW: -7.9% $MSTR: -9.9% One of those weeks. Next weeks earning reports will be interesting. NFA. DYOR. Weekly Portfolio Performance: $VIST: +14.3% $CRMD: +6.7% $IREN: -5.2% $DCTH: [----] $SEZL: -6.5% $PSIX: -7.3% $QXO: -7.3%"
X Link @Fund_Stocks 2026-02-07T23:52Z [--] followers, [---] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing